Lanitop

Metildigoxin, the active ingredient in Lanitop, is a cardiac glycoside presented as an oral dosage form for oral use. It is employed in the management of congestive heart failure and certain atrial arrhythmias, improving cardiac contractility and controlling ventricular rate.

GNH USA supplies Lanitop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to European Union quality standards and provides regulatory documentation for import.

Metildigoxin is used in cardiac conditions that involve impaired contractility or abnormal atrial rhythm.

Congestive heart failure: enhances myocardial contractility, reducing symptoms such as dyspnea and edema. Atrial fibrillation: slows atrioventricular nodal conduction, helping to control ventricular rate. Atrial flutter: improves rate control by increasing AV nodal refractory period.

Metildigoxin may be associated with a range of adverse reactions, varying from mild to potentially life‑threatening.

Common Side Effects: - Nausea - Vomiting - Diarrhea - Fatigue - Visual disturbances (e.g., blurred vision, yellow‑green tint)

Serious or Rare Side Effects: - Cardiac arrhythmias (e.g., ventricular tachycardia) - Severe bradycardia - Hyperkalemia - Acute heart block

When prescribing Metildigoxin, clinicians should observe several safety measures to minimize risk.

Monitor serum electrolytes: check potassium and magnesium levels regularly to avoid toxicity. Assess renal function: dose adjustments may be needed in impaired clearance. Evaluate cardiac rhythm: baseline ECG is recommended before initiation. Educate patients: advise on signs of toxicity such as visual changes or palpitations. Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture.

Metildigoxin interacts with several drug classes, requiring careful review of concomitant therapy.

Major Interactions (Avoid): - Potassium‑sparing diuretics: may increase risk of hyperkalemia and reduce drug efficacy. - Amiodarone: can potentiate digoxin‑like toxicity through pharmacokinetic inhibition. - Macrolide antibiotics (e.g., erythromycin): raise plasma concentrations, heightening toxicity risk.

Moderate Interactions (Monitor Closely): - Loop diuretics: alter electrolyte balance, necessitating closer monitoring. - Beta‑blockers: additive effects on heart rate and AV nodal conduction. - ACE inhibitors: may enhance digoxin levels indirectly via renal effects.